PHYSIOMICS PLC |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.549 GBX | +3.27% |
|
-0.06% | -3.19% |
| Mar. 18 | Transcript : Physiomics Plc, H1 2024 Earnings Call, Mar 18, 2024 | |
| Mar. 18 | Physiomics celebrates "substantial" contract with old client | AN |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Physiomics PLC is a United Kingdom-based company, which provides consulting services to pharmaceutical companies in the areas of outsourced quantitative pharmacology and computational biology. The Company offer its services by utilizing its proprietary Virtual Tumour predictive software, industry standard tools (such as NONMEM and MATLAB), as well as developing bespoke models using the R programming language. Virtual Tumour is a predictive quantitative systems' pharmacology (QSP) model used worldwide by global pharmaceuticals to small biotech companies to support oncology Research and development (R&D). It is a semi-mechanistic model that incorporates an abstracted representation of the cell cycle, Deoxyribonucleic acid (DNA) damage/ repair and elements of the immune response. The Company is also developing its technology for use in the field of personalized medicine. The Company is focused on helping pharma and biotech clients.
Calendar
2024-09-25
- Q4 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -3.19% | 2.55M | |
| -5.72% | 130B | |
| +8.31% | 69.31B | |
| -15.68% | 37.79B | |
| +9.36% | 36.04B | |
| -11.34% | 16.12B | |
| +10.48% | 14.74B | |
| +11.64% | 10.56B | |
| -23.43% | 4.74B | |
| -19.91% | 4.15B |
- Stock Market
- Equities
- PYC Stock
- News Physiomics Plc
- Physiomics Wins DNA-related Modeling Contract with Large Pharmaceutical Company
